Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2010, Article ID 836214, 4 pages
Case Report

Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

1Department of Psychiatry, University of Florence, Florence, Italy
2Institute of Neurosciences, Florence, Italy
3Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA

Received 14 December 2009; Accepted 9 March 2010

Academic Editor: Tian Po Oei

Copyright © 2010 Chiara Cecchelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.